FDA-2026-P-4022

Requests that the FDA Refuse to approve the Handa 505(b)(2) cabozantinib lauryl sulfate product submitted under NDA 220613, and any cabozantinib lauryl sulfate products with similar GTI and bioequivalence deficiencies, because available evidence shows that the salt switch has resulted in significant changes that are likely to raise novel questions of safety and effectiveness